Business
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively
About this update from Surrozen, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021, organized by the American Association for the Study of Liver Diseases (AASLD) and held November 12-15. “The data presented at the AASLD conference represent important developments in Surrozen’s liver research program for SZN-043,” said Scott Friedman, MD, Dean for Therapeutic Discovery and Chief of the Division of Liver Studies at the Icahn School of Mount Sinai. “These preclinical studies are encouraging and demonstrate progress in identifying and measuring non-invasive serum markers that have the potential to provide an early assessment of Wnt signal activation and restoration of liver function as the program advances toward Phase 1 clinical trials.” In a poster titled, “SZN-043 Improves Liver Metabolic Function in a Mouse Preclinical Model,” the data showed that methacetin quantification after IV dosing in mice can be used to demonstrate that SZN-043 can quickly increase liver function and that the duration of this effect is transient but can last beyond effects on gene regulation. The poster titled “Non-Invasive Pharmacodynamic Markers of SZN-043 Target Engagement and Wnt Pathway Activation,” analyzed the effect of SZN-043 on non-invasive pharmacodynamic markers of target occupancy and Wnt/β-catenin activation in normal mice treated with a single dose of SZN-043 at increasing doses. Target occupancy was evaluated by measuring serum alkaline phosphatase (ALP) as SZN-043 binds to the ASGR receptor and increases ALP serum concentration by interfering with ALP elimination occurring through the ASGR receptor. Wnt/β-catenin activation was evaluated by measuring serum leukocyte cell-derived chemotaxin-2 (LECT2), a direct Wnt target gene. The results showed that serum ALP concentrations and LECT2 concentrations increased in a dose-dependent manner and that these markers can be used as non-invasive pharmacodynamic markers of SZN-043 target occupancy and Wnt activation, respectively. Consistent with the observation of interfering with ALP ...